Associations between neck circumference and markers of dysglycemia, non-alcoholic fatty liver disease, and dysmetabolism independent of Body Mass Index in an Emirati population.
MetS
NAFLD
dysglycemia
neck circumference
obesity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
04
2022
accepted:
10
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Neck circumference (NC) is quick and easy to measure and may be a useful surrogate marker for body composition. We investigated NC as a potential marker of dysglycemia, MetS, and NAFLD. 674 individuals were recruited at the Imperial College London Diabetes Centre in a study of sleep apnea prevalence. Of these, 547 (Age 46 ± 11.4 years, Body Mass Index (BMI) 31 ± 6 kg/m Adjusted for BMI, sex, and age, NC was 0.65 ± 0.3 cm greater in prediabetes (p = 0.0331), and 1.07 ± 0.28 cm greater in T2DM, compared with NGT (p = 0.0002). Adjusting for BMI, sex, and glycemic status, 1-cm increase in NC was associated with a 1.04 ± 1.01 U/L (p <0.0001) increase in ALT and, additionally, correcting for statin use, a 0.03 ± 0.01 mmol/L reduction in HDL (p <0.0001) and a 0.1 ± 0.02 increase in TC : HDL. A 1 cm increase in NC was associated with a 1.15 ± 1.02% (p <0.0001) increase in 10-year AHA cardiovascular risk in individuals over 40 years old and a 0.16 ± 0.02 (p <0.0001) increase in NAFLD fibrosis score. The neck circumference was associated with the hazard of new onset of deranged ALT adjusted for age, sex, glycemic status, and BMI (hazard ratio 1.076 (95% CI 1.015-1.14, p = 0.0131) and with the incidence of Fatty Liver Index associated with high probability of NAFLD (hazard ratio 1.153 (95% CI 1.019-1.304), p = 0.0239). NC is associated with dysglycemia, components of the MetS, and factors predictive of NAFLD, but does not appear to independently predict subsequent progression to high risk of liver fibrosis in this predominantly diabetic population.
Identifiants
pubmed: 36147574
doi: 10.3389/fendo.2022.929724
pmc: PMC9485482
doi:
Substances chimiques
Biomarkers
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
929724Informations de copyright
Copyright © 2022 Fojas, Buckley and Lessan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Exp Clin Cardiol. 2006 Spring;11(1):14-20
pubmed: 18651013
Hiroshima J Med Sci. 2014 Dec;63(4):27-32
pubmed: 25707090
Ann Hum Biol. 2017 Dec;44(8):667-677
pubmed: 29037078
Am J Gastroenterol. 2017 Jan;112(1):18-35
pubmed: 27995906
J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S57-63
pubmed: 18987271
Microvasc Res. 2021 Jul;136:104149
pubmed: 33647342
BMC Public Health. 2021 Aug 31;21(1):1605
pubmed: 34465314
Rev Assoc Med Bras (1992). 2018 Jan;64(1):54-62
pubmed: 29561943
Nutrition. 1999 Jan;15(1):89-90; discussion 91
pubmed: 9918082
Obes Surg. 2021 Aug;31(8):3675-3685
pubmed: 33982243
Diabetologia. 2008 Nov;51(11):2041-8
pubmed: 18712345
Am J Clin Nutr. 1990 Apr;51(4):571-7
pubmed: 2321565
Am J Hypertens. 2004 May;17(5 Pt 1):409-14
pubmed: 15110899
Front Public Health. 2022 Jan 24;9:811006
pubmed: 35141192
Public Health. 2021 Sep;198:301-306
pubmed: 34507136
Diabetol Metab Syndr. 2021 Mar 2;13(1):25
pubmed: 33653388
Endocrine. 2017 Mar;55(3):822-830
pubmed: 27796813
Open Access Maced J Med Sci. 2015 Dec 15;3(4):578-81
pubmed: 27275290
Nutr Metab (Lond). 2021 Mar 17;18(1):30
pubmed: 33731171
J Clin Endocrinol Metab. 2010 Aug;95(8):3701-10
pubmed: 20484490
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
Endocr Res. 2018 Aug;43(3):186-194
pubmed: 29624091
Prim Care Diabetes. 2020 Jun;14(3):265-273
pubmed: 31530470
Int J Obes (Lond). 2008 Aug;32 Suppl 3:S56-9
pubmed: 18695655
Turk J Gastroenterol. 2019 Feb;30(2):163-170
pubmed: 30541716
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):127-33
pubmed: 17095717
Obes Rev. 2015 Jan;16(1):1-12
pubmed: 25407540
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):657-674
pubmed: 29779782
Lancet Diabetes Endocrinol. 2013 Oct;1(2):152-62
pubmed: 24622321
Nutr Metab (Lond). 2015 Dec 30;12:63
pubmed: 26719755
J Pediatr Endocrinol Metab. 2020 Feb 25;33(2):205-213
pubmed: 31846425
Clin Endocrinol (Oxf). 2013 Jun;78(6):874-81
pubmed: 22804918
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
Indian J Endocrinol Metab. 2018 May-Jun;22(3):347-354
pubmed: 30090726
Sci Rep. 2019 Nov 25;9(1):17437
pubmed: 31767874
Hepatol Int. 2021 Aug;15(4):912-921
pubmed: 33822317
Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):312-9
pubmed: 20628304
Nutr Metab Cardiovasc Dis. 2016 Jun;26(6):510-6
pubmed: 27089975
Obes Res. 2001 Aug;9(8):470-7
pubmed: 11500527
Diabetol Metab Syndr. 2018 Sep 29;10:72
pubmed: 30288175
Ther Adv Cardiovasc Dis. 2017 Aug;11(8):215-225
pubmed: 28639538
Biomed Res Int. 2021 Nov 22;2021:2365399
pubmed: 34853788
Clin Gastroenterol Hepatol. 2021 Dec 29;:
pubmed: 34971806
BMJ Open. 2014 Feb 06;4(2):e004138
pubmed: 24503301
Endocrine. 2012 Oct;42(2):335-42
pubmed: 22407493
Am J Clin Nutr. 2014 Nov;100(5):1244-51
pubmed: 25332322
BMC Pediatr. 2016 Mar 08;16:31
pubmed: 26956385
Front Endocrinol (Lausanne). 2021 May 31;12:697437
pubmed: 34135867
PLoS One. 2022 Feb 17;17(2):e0263826
pubmed: 35176047
Obes Rev. 2016 Oct;17(10):989-1000
pubmed: 27405510
Endocr Rev. 2018 Apr 1;39(2):79-132
pubmed: 29518206
Nutrients. 2021 Aug 30;13(9):
pubmed: 34578907
J Pak Med Assoc. 2012 Jan;62(1):36-40
pubmed: 22352099
PLoS One. 2015 Feb 13;10(2):e0118071
pubmed: 25679378
J Hepatol. 2022 Oct;77(4):1219-1221
pubmed: 35764234
Int J Endocrinol. 2020 May 16;2020:7982107
pubmed: 32508918